血管生成
血管生成拟态
单克隆抗体
癌症研究
胶质瘤
激酶插入结构域受体
生物
川地34
MMP2型
MMP9公司
免疫组织化学
血管内皮生长因子
血管内皮生长因子A
抗体
细胞生物学
免疫学
血管内皮生长因子受体
癌症
下调和上调
干细胞
转移
遗传学
生物化学
基因
作者
Sansong Chen,Xuetao Li,Hao Wang,Guangliang Chen,Youxin Zhou
标识
DOI:10.1016/j.bbrc.2022.03.045
摘要
Angiogenesis is a key physiological process that plays a key role in glioblastoma (GBM) progression and displays therapeutic resistance to antiangiogenic therapies. In this study, we aimed to identify whether vascular endothelial growth factor receptor 2(VEGFR2)monoclonal antibodies(mab)could inhibit tumorigenicity and the formation of vascular mimicry (VM) in GBM. The bioinformatic analysis from TCGA, CGGA, and TCPA databases and Immunohistochemistry (IHC) revealed that VEGFR2 is highly expressed in glioma tissues and results in a poor prognosis and is positively associated with VM markers (CD34 and PAS). The anti-VEGFR2 monoclonal antibodies(MSB0254)could inhibit the invasion, migration, and VM formation of U251 and primary glioma cells in vitro. In vivo, MSB0254 (m) could not only inhibit the growth of transplanted tumors of U251 and GL261 cells, but also significantly inhibit the expression of CD34, VEGFR2, Ki67, MMP2, MMP9 and reduce the expression of CD34/PAS and inhibit VM formation. The VEGFR2 monoclonal antibody could inhibit the angiogenesis and tumor growth of GBM by blocking the signaling pathway mediated by VEGFR2. It may become a new supplementary treatment for GBM.
科研通智能强力驱动
Strongly Powered by AbleSci AI